Trial · NCT02564198
Adverse events492
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 492
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Anaemia | Blood and lymphatic system disorders | 8 mg/kg Ramucirumab (Part A) | 2 | 8 | 4 |
| other | Anaemia | Blood and lymphatic system disorders | 12 mg/kg Ramucirumab (Part A) | 9 | 15 | 9 |
| other | Anaemia | Blood and lymphatic system disorders | 12 mg/kg Ramucirumab (Part B) | 2 | 6 | 3 |
| other | Eosinophilia | Blood and lymphatic system disorders | 8 mg/kg Ramucirumab (Part A) | 0 | 8 | 0 |
| other | Eosinophilia | Blood and lymphatic system disorders | 12 mg/kg Ramucirumab (Part A) | 1 | 15 | 1 |
| other | Eosinophilia | Blood and lymphatic system disorders | 12 mg/kg Ramucirumab (Part B) | 0 | 6 | 0 |
| other | Sinus bradycardia | Cardiac disorders | 8 mg/kg Ramucirumab (Part A) | 1 | 8 | 1 |
| other | Sinus bradycardia | Cardiac disorders | 12 mg/kg Ramucirumab (Part A) | 1 | 15 | 1 |
| other | Sinus bradycardia | Cardiac disorders | 12 mg/kg Ramucirumab (Part B) | 0 | 6 | 0 |
| other | Sinus tachycardia | Cardiac disorders | 8 mg/kg Ramucirumab (Part A) | 2 | 8 | 2 |
| other | Sinus tachycardia | Cardiac disorders | 12 mg/kg Ramucirumab (Part A) | 5 | 15 | 7 |
| other | Sinus tachycardia | Cardiac disorders | 12 mg/kg Ramucirumab (Part B) | 2 | 6 | 3 |
| other | Ear pain | Ear and labyrinth disorders | 8 mg/kg Ramucirumab (Part A) | 0 | 8 | 0 |
| other | Ear pain | Ear and labyrinth disorders | 12 mg/kg Ramucirumab (Part A) | 0 | 15 | 0 |
| other | Ear pain | Ear and labyrinth disorders | 12 mg/kg Ramucirumab (Part B) | 1 | 6 | 1 |
| other | Hypoacusis | Ear and labyrinth disorders | 8 mg/kg Ramucirumab (Part A) | 0 | 8 | 0 |
| other | Hypoacusis | Ear and labyrinth disorders | 12 mg/kg Ramucirumab (Part A) | 1 | 15 | 1 |
| other | Hypoacusis | Ear and labyrinth disorders | 12 mg/kg Ramucirumab (Part B) | 0 | 6 | 0 |
| other | Hyperthyroidism | Endocrine disorders | 8 mg/kg Ramucirumab (Part A) | 1 | 8 | 1 |
| other | Hyperthyroidism | Endocrine disorders | 12 mg/kg Ramucirumab (Part A) | 0 | 15 | 0 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02564198/events